Fig. 2
From: Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
No hypoxia-selective cytotoxicity of menadione and gemcitabine 4 days post-treatment. DU145 (a–c), PC3 (D-F) and LNCaP (g–i) cell lines were exposed to menadione, gemcitabine or tirapazamine under normoxia or 0.1% O2 hypoxia. Only tirapazamine demonstrated hypoxia selective cytotoxicity in the cell lines. The data points represent the mean ± SEM of 2–4 values taken from each biological repeat, within each biological repeat there were 6 intra-assay replicates. Statistical analysis was performed using multiple t-tests with Holm-Sidak correction. **indicates p < 0.01